High-volume Centers Research Articles

PROsthetic MEsh Reinforcement in elective minimally invasive paraesophageal hernia repair (PROMER): an international survey.

The optimal treatment for paraesophageal hiatus hernia (PEH) is controversial. While crural buttressing with mesh shows promises in reducing recurrences, the decision to use mesh during minimally invasive PEH repair is largely subjective. Due to these uncertainties, we conducted a survey to examine current clinical practices among surgeons and to assess which are the most important determinants in the decision-making process for mesh placement. Thirty-five multiple-choice Google Form-based survey on work-up, surgical techniques, and issues are considered in the decision-making process for mesh augmentation during minimally invasive PEH repair. Responses were graded on a 5-point Likert scale and analyzed using descriptive statistics. Consensus was defined as > 70% of participants agreed (agree or strongly agree) on a specific statement. Overall, 292 surgeons (86% from Europe) participated in the survey. The median age of participants was 42years (range 29-69). The median number of PEH procedures was 25/year/center (range 5-400), with 67% of participants coming from high-volume centers (> 20 procedures/year). Consensus on use of mesh was reached for intraoperative findings of large (> 50% of intrathoracic stomach) PEH (74.3%), crural gap with > 4cm distance between right and left crus (77.1%), and/or crural atrophy with < 0.5cm thickness of one or both pillars (73%), and for redo surgery (71.9%). Further, consensus was reached in defining recurrence as a combination of refractory symptoms and anatomical/radiological evidence of > 2cm hernia. This survey shows that large PEH, wide crural transverse diameter, fragile crura, and redo surgery are the most influential issues driving the decision for mesh-reinforced cruroplasty.

Safety and efficacy of high thoracic epidural analgesia for chest wall surgery in young adolescents: A retrospective cohort analysis and a new standardised definition for success rate.

Chest wall surgery for the correction of pectus excavatum or pectus carinatum has gained increased interest in recent years. Adequate pain treatment, respiratory physiotherapy and early ambulation are key to improving the outcomes. Although thoracic epidural analgesia is highly effective, its safety is controversial, leading to extensive scrutiny and questioning of its role. We hypothesise that thoracic epidural analgesia is effective and well tolerated to use in adolescents, with a high success rate and low pain scores. Observational retrospective cohort study. All adolescent cases in a high-volume academic tertiary chest wall surgery centre between March 1993 and December 2017 were included. A total of 1117 patients aged from 12 to 19 years of age and receiving either Ravvitch, Nuss or Abramson chest wall reconstruction for pectus excavatum were identified in our institutional chest wall surgery database. After applying selection and exclusion criteria, 532 patients were included in the current analysis. The primary endpoint of this study was the safety of epidural analgesia, assessed by the incidence of acute adverse events. Secondary endpoints were block success rates using a specific novel definition, and analgesic efficacy using recorded postoperative pain scores. More than 60% of patients experienced one or more adverse events. However, all events were minor and without consequences. No serious or long-term adverse events were detected. The success rate of thoracic epidural placement was 81%. Low postoperative pain scores were observed. Thoracic epidural analgesia is an extremely effective pain control technique, with a surprisingly high number of minor adverse events but safe with regard to serious adverse events. The local research ethics committee approved and registered this study on 16 May 2022 (registration number: S66594).

Hypoalbuminemia is a predictor of mortality in patients with cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation.

Hypoalbuminemia is predictive of mortality in critically ill patients, especially those with cardiac etiologies of illness. The objective of this study was to determine the association of albumin level pre-cannulation for veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO) and important clinical hospital outcomes. This was a retrospective, observational cohort study of albumin levels in patients with cardiogenic shock requiring V-A ECMO between December 2015 and August 2021 in a single, high-volume ECMO center. The primary outcome was in-hospital mortality. Of 434 patients assessed, 318 were included. The overall mean pre-ECMO albumin was 3 ± 0.8g/dL and mean albumin at 72 hours post-cannulation was 2.7 ± 0.5g/dL. For patients with pre-ECMO albumin ≤3g/dL vs. >3g/dL, in-hospital mortality was 44.9% vs. 27.5%, respectively (p = .002). In multivariable logistic regression analysis, higher albumin (per 1g/dL increase) at time of V-A ECMO initiation was associated with decreased odds of in-hospital mortality (OR, 0.68; 95% CI, 0.48-0.96; p = .03). Patients with a pre-ECMO albumin ≤3g/dL required significantly more platelet transfusions and had higher incidence of gastrointestinal bleeding during V-A ECMO support (both p < .05). Hypoalbuminemia at time of cannulation is significantly associated with in-hospital mortality and ECMO-related complications including platelet transfusion and gastrointestinal bleeding. Albumin levels at the time of consideration of V-A ECMO may serve as a key prognostic indicator and may assist in effective decision-making regarding this invasive and costly resource.

Use of sirolimus-coated balloon in de novo coronary lesions; long-term clinical outcomes from a multi-center real-world population.

Sirolimus-coated balloon (SCB), a relatively novel technology appears attractive due to the drug properties (safety and efficacy) and sirolimus remains the drug of choice in stents. However, there is limited data long-term data on SCB. In this study, we have explored the clinical outcomes following the use of SCB in de-novo lesions from a real-world practice. To report long-term clinical outcomes following the use of Siroliumus coated balloon in de novo lesions. We analyzed all patients treated with an SCB in de novo lesions between 2016 and 2023 at four high-volume centers in UK and Italy. The outcomes measured included cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularization (TLR) and major adverse cardiac events (MACE). During the study period, 771 patients had SCB in de novo lesions. Diabetes mellitus was noted in 36% of patients (n = 280), of which 14% (n = 108) were insulin dependent. Fifteen percent (n = 117) had chronic kidney disease, Fifty-two percent (n = 398) of cases were in the setting acute coronary syndrome (ACS) and of which 51 cases (7%) were ST-segment elevation myocardial infarction. Small vessels (<3.0 mm) accounted for 78% (n = 601) of cases and 76% (n = 584) were long lesions ( 20 mm). The mean diameter of SCB was 2.6 ± 0.4 mm and the mean length was 25 ± 10.39 mm. Bailout stenting following SCB was required in 9% lesions (n = 67). During the median follow-up 640 days, total death occurred in 39 (5%) patients and of which, cardiac death occurred in 10 patients (1.3%). TVMI occurred in 20 patients (2.6%). TLR and TVR were 5.6% and 5.8% respectively. The overall MACE rate was 8%. We had no documented case of acute vessel closure. The results from this long-term follow-up in a real-world population are encouraging with low rates of hard endpoints and acceptable rates of TLR and MACE despite a complex group of patients. Our data suggest that SCBs are safe in coronary intervention with good clinical outcomes in the long term.

Adjunctive venous sinus stenting in transvenous embolization of vein of Galen malformations.

Vein of Galen malformations are congenital arteriovenous malformations primarily treated by endovascular embolization via transarterial or transvenous approaches. transvenous embolization can be utilized to close the malformation but may be difficult in patients with venous stenosis or blockages, which drive venous hypertension and lead to significant neurologic consequences. Here, we illustrate the atypical placement of an intracranial venous sinus stent to improve outflow after transvenous embolization in pediatric patients with the vein of Galen malformation. A retrospective review of clinical databases at two high-volume endovascular centers from January 2018 to March 2023 identified all vein of Galen malformation patients who received a venous sinus stent during transvenous embolization. Clinical data, imaging, angioarchitecture, operative details, postoperative management, and follow-up were reviewed. Three patients presented for transvenous embolization after multiple staged transarterial embolizations of their vein of Galen malformation. Transvenous access was complicated by lateral sinus stenosis, which was temporarily relieved by balloon angioplasty. After transvenous embolization by pressure cooker technique, the dural sinuses were stented using the existing venous guide catheter. Venous angiography demonstrated improved flow across the stenosed areas and post-embolization angiography demonstrated normalized venous drainage with widely patent stents. One patient experienced postoperative oculomotor nerve palsy unrelated to the stent placement. All patients demonstrated a complete cure of their vein of Galen malformations with patent venous sinus stents on follow-up. In patients with the vein of Galen malformation and venous hypertension receiving transvenous embolization, venous sinus stenting may be a safe and effective option to reduce aberrant cortical venous drainage and improve normal outflow. Further studies are warranted to investigate its benefit in high-flow vascular malformations.

National Trends and Outcomes of Pedal Bypass Surgery

ObjectiveThe technical demands associated with pedal bypass (PB) surgery place it at risk of underutilization and may be limiting its widespread adoption as a valuable revascularization modality. This study aims to evaluate trends in PB performance, assess its outcomes, and compare its results between high- and low-volume centers. MethodsAll patients receiving a PB between 2003 and 2023 were identified in the Vascular Quality Initiative (VQI) infrainguinal bypass (IIB) module. The ratio of PB to total IIB performed was calculated for each year and trended over the study period. Centers performing PB were categorized according to their annual PB volume into tertiles of low-volume centers (LVC, <2 PB/year), medium-volume centers (MVC, 2-4 PB/year), and high-volume centers (HVC, >4 PB/year) for comparison. Patient characteristics and outcomes were compared using the χ2 or Fisher exact test as appropriate for categorical variables and the analysis of variance test or Kruskal-Wallis test as appropriate for continuous variables. Cox regression analysis was used to study the association between center volume and the primary outcomes of primary patency, primary-assisted patency, secondary patency, reintervention, amputation, and major adverse limb events (MALE), defined as the composite outcome of amputation and/or reintervention. ResultsA total of 3466 patients received a PB during the study period. The ratio of PB to IIB dropped from 14% to 4% between 2003 and 2023. Primary, primary-assisted, and secondary patency rates were 65%, 76%, and 80%, respectively, and limb salvage rate was 83% at 1 year. Nineteen percent of centers performing IIBs in the VQI did not perform any PBs during the study period. Of the 246 centers performing PBs, 78% were LVC, 15% were MVC, and only 7% were HVC. On Cox regression analysis, HVCs were associated with a lower risk of primary patency loss (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.66-0.95; P = .010), reintervention (HR, 0.75; 95% CI, 0.60-0.95; P = .016), amputation (HR, 0.77; 95% CI, 0.61-0.98; P = .034), and MALE (HR, 0.78; 95% CI, 0.66-0.93; P = .005) compared with LVCs. No difference in secondary patency between high- and low-volume centers was observed (P = .680). ConclusionsThe utilization of PB operations experienced a four-fold decrease over the past 20 years, despite favorable patency and limb salvage outcomes. Centers with a higher operative volume in PB achieve better outcomes than LVCs, and accordingly, patients with extensive tibioperoneal disease may benefit from evaluation at centers with documented expertise in PB before resorting to an alternative revascularization modality or a major limb amputation.

Evolving Role of Coronary Collaterals in STEMI Outcomes: A Comparative Analysis of Pandemic and Post-Pandemic Phases.

Acute ST-elevation myocardial infarction (STEMI) is a critical condition where coronary collaterals can mitigate myocardial damage. The Coronavirus Disease 2019 (COVID-19) pandemic introduced unique challenges in STEMI management, potentially affecting outcomes. This study evaluates the efficacy of coronary collaterals during the pandemic compared to the post-pandemic period. A review of 1465 STEMI patients treated at a high-volume tertiary care center from April 2020 to December 2022 was conducted. Collaterals were assessed using the Rentrop classification. In-hospital mortality and 1-year major adverse cardiac events (MACE) were analyzed based on collateral status and timeframes. During the pandemic, there was a higher incidence of robust collaterals (28.2% vs 23.2%, P = .04), but they were less protective, with similar in-hospital mortality (14.4% vs 8.1%, P = .07) and 1-year MACE rates (21.9% vs 30.4%, P = .09) across groups. Post-pandemic, robust collaterals showed significant protective effects with reduced in-hospital mortality (3.6% vs 7.4%, P = .04) and 1-year MACE rates (17.1% vs 24.9%, P = .03). These findings highlight a dynamic role of collaterals in STEMI management, with the pandemic impairing their functionality. This underscores the need for adaptive STEMI care strategies, especially during global health crises.

Initial cannulation strategy impacts perioperative outcomes of acute type A dissection in high-volume centers

ObjectiveWe performed an intention-to-treat analysis of initial cannulation strategy to assess the impact on perioperative outcomes in acute type A dissection using multicenter data. MethodsAll patients undergoing surgical repair of acute type A dissection from a multicenter national registry of 9 high-volume aortic centers were analyzed. Cannulation strategies included in the analysis were axillary, femoral, direct aortic, and innominate. Among 950 patients, we excluded those with chronic syndromes, type B dissections, and unknown initial cannulation strategy. Patients with multiple cannulation strategies were included if the sequence in which strategies were initiated was known. The final cohort consisted of 936 patients. Primary outcomes were stroke and death. Multivariable logistic regression was performed to adjust for baseline differences. P values represent Tukey's post hoc comparisons. ResultsAmong 936 patients, cannulation strategies in descending order included axillary (n = 502, 53%), femoral (n = 268, 29%), aortic (n = 104, 11%), and innominate (n = 59, 6%). Of these patients, 46 (5%) had a change in the initial cannulation strategy before initiating circulatory arrest, mainly for poor axillary flow or initial femoral cannulation for hemodynamic instability followed by axillary. Patients in the femoral group were younger (61.3 ± 13.8 years) than patients in the aortic group (66.4 ± 12.52 years, P = .01) and more likely to present with malperfusion (n = 123, 45.9%) compared with patients in the aortic, axillary, and innominate groups (P < .01). Patients in the femoral group also had the longest duration of cerebral ischemia (femoral: 16.9 ± 16 minutes, aortic: 11.5 ± 11.8 minutes; axillary: 4.41 ± 10.3 minutes; innominate: 2.53 ± 6 minutes, P < .01 for all vs femoral). Unadjusted risk of death, stroke, and prolonged ventilation was lowest in the axillary and innominate groups. Length of stay was also reduced in the innominate group. Multivariable regression demonstrated axillary (odds ratio [OR], 0.52; 0.36-0.75; P = .004) and innominate (OR, 0.19; 0.07-0.54; P = .009) cannulation to be associated with a significantly reduced risk of stroke. A nonsignificant indication of reduced death in patients receiving axillary cannulation remained (OR, 0.66; 0.45-0.96; P = .07). ConclusionsIn high-volume aortic centers, an initial cannulation strategy using axillary access is associated with reduced risk of stroke compared with femoral access. Axillary cannulation should be the preferred strategy in experienced centers if anatomy and stability allow.

The association of Medicaid expansion and parathyroidectomy for benign disease: Insurance status remains an important factor in access to high-volume centers

BackgroundMedicaid expansion has been associated with improved access to surgical care at high-volume centers. Its impact on parathyroidectomy, however, is unclear. We evaluated the association between Medicaid expansion and parathyroidectomy at high- and low-volume centers. MethodsThe Vizient Clinical Data Base was queried for parathyroidectomies. Patients were grouped by insurance status and pre- and post-Medicaid expansion periods. Hospitals were stratified into tertiles (T1-T3) by operative volume (T1 = highest-volume centers). Odds of parathyroidectomy and a difference-in-differences analysis were conducted. ResultsIn total, 31,983 patients were identified. Patients were predominantly privately insured (49.9%). Uninsured and Medicaid patients had increasing odds of operation at lower-tertile centers (odds ratio: T1 = ref; uninsured: T2 = 10.0, T3 = 15.8; Medicaid: T2 = 6.2, T3 = 13.5; P < .001). Medicare patients, however, were less likely to undergo operation at lower-volume centers (odds ratio: T2 = 0.89, P < .001; T3 = 0.92, P = .002). Privately insured patients were the least likely to receive care at low-volume centers (odds ratio: T3 = 0.7, P < .001).Medicaid patients in nonexpansion states had 12–16 times higher odds of parathyroidectomy at lower-volume hospitals than their counterparts in expansion states (expansion/nonexpansion states: pre-expansion T3 = 2.3/28.0; postexpansion T3 = 1.3/21.4). Expansion was associated with an increase in the proportion of parathyroidectomy for Medicaid patients, with larger gains seen at higher-volume centers (T1 = 5.0%, P = .01; T2 = 3.1%, P = .001; T3 = 2.7%, P = .03). Expansion was not associated with changes in payor distribution for uninsured, Medicare, or privately insured patients. ConclusionsMedicaid expansion was associated with an increase in parathyroidectomy for Medicaid patients at high-volume centers. However, in nonexpansion states, access to surgical treatment at high-volume centers remains limited for uninsured and underinsured patients.

Impact of Center Volume on the Use of Status 2 Exceptions for Heart Transplantation.

There are limited data examining the relationship between transplant center volume and their use of Status 2 exceptions for heart transplant (OHT). A retrospective review of the Organ Procurement and Transplantation Network (OPTN) database identified all patients undergoing OHT under Status 2 exception between late 2018 and early 2023. Demographics were collected and transplant centers were categorized based on the number of OHT performed annually (very low volume = < 5 OHT per year; low volume = 5-24 OHT per year; medium volume = 25-50 OHT per year, high volume = > 50 OHT per year). Across all centers, 6348 OHT were included, with n = 68 performed at very low volume centers, n = 1001 performed at low volume centers, n = 1834 performed at medium volume centers, and n = 3445 performed at high volume centers. Medium and high volume centers applied for at least one Status 2 exception about 30%-35% of the time, compared to 50%-60% of the time observed at very low and low volume centers. Compared to very low volume centers, medium volume centers applied for half the amount of Status 2 exceptions (IRR = 0.52 [0.35-0.76]; p < 0.001) while high volume centers applied for less than half the amount (IRR = 0.42 [0.29-0.62]; p < 0.001). High-volume centers were also 18% less likely to apply for exceptions than medium-volume centers (IRR = 0.82 [0.74-0.91]; p < 0.001). Lower volume transplant centers apply for Status 2 exceptions at a significantly higher rate, with a stepwise decrease in exception use with increasing transplant center volume.

S1298 Artificial Intelligence-Assisted Colonoscopy Improves PDR in Patients With IBD: A Cohort Study in a High Volume Center

S1298 Artificial Intelligence-Assisted Colonoscopy Improves PDR in Patients With IBD: A Cohort Study in a High Volume Center

Achievement of international benchmark outcomes for robotic pancreaticoduodenectomy in a low volume country

BackgroundRecently, there has been an increase in the utilisation of the robotic platform to perform minimally invasive pancreaticoduodenectomy in high volume centres, with the goal of reducing morbidity and improving patient outcomes. This study reports the successful implementation of a robotic pancreaticoduodenectomy (RPD) programme in the relatively low volume setting of Australia, measured against established, internationally accepted benchmarks for low-risk open pancreaticoduodenectomy (OPD). MethodsRetrospective review of a prospectively maintained database for consecutive RPD at two Brisbane hospitals was performed, comparing data to internationally established benchmarks for low-risk OPD. A structured RPD programme was implemented by two surgeons across a study period spanning May 2017 to December 2023. ResultsOver the study period, seventy-two consecutive RPDs were performed, with 79 % for malignancy. Perioperative outcomes for transfusions, conversion rate, postoperative fistula rate, morbidity, mortality and oncological outcomes were all within established benchmark cutoffs for low-risk open pancreaticoduodenectomy (OPD), although operative time exceeded the benchmark value by 0.7hrs. ConclusionA carefully implemented RPD programme in the low volume Australian setting is feasible, with high quality outcomes achievable when compared to established benchmarks for low-risk OPD and to reported RPD series published by high volume pioneering centres.

Uncommon Presentation Of A Giant Retroperitoneal Liposarcoma: A Peculiar Case Study

Introduction: Soft tissue sarcomas constitute less than 1% of all neoplasms, with approximately one-third of malignant tumors in the retroperitoneum being sarcomas. Among these, liposarcoma emerges as the most prevalent type. Retroperitoneal liposarcomas with intraperitoneal extension and extension into the inguinal canal are relatively uncommon, presenting a challenge for treatment due to their local aggressiveness and clinical nonspecificity. The clinical difficulty in managing these cases is exacerbated by patients often seeking medical attention late in the disease progression. The slow development and the scarcity of symptoms in the early stages contribute to delayed reporting. Consequently, these tumors are recognized for their capacity to reach enormous sizes before being diagnosed and addressed. Case Report: We present a case involving a 52-year-old man who underwent surgical resection for a massive, well-differentiated retroperitoneal liposarcoma. This tumor exhibited intraperitoneal extension and weighed a substantial 6.8 kilograms. Discussion: Retroperitoneal liposarcomas (RPS) frequently manifest as large, locally advanced lesions. The occurrence of RPS with intraperitoneal extension and extension into the inguinal canal is relatively uncommon. The clinical presentation is often delayed, attributed to the expansive nature of the retroperitoneal space. Evaluating these tumors necessitates a comprehensive, multimodal approach. Given that most RPS are characterized as low-grade, distant metastasis is infrequent, and the primary challenge lies in achieving effective local control and preventing recurrence. The preferred treatment involves radical resection of these tumors, incorporating en bloc resection of involved structures. In certain cases, the strategic use of neoadjuvant and adjuvant therapies, tailored to specific tumor histologies, may enhance local control and overall survival. Conclusion: Effectively managing retroperitoneal liposarcomas necessitates a multidisciplinary approach, ideally conducted at high-volume centers that specialize in the treatment of patients facing these intricate malignancies. Existing data indicate that radical resection stands as the primary opportunity for a cure. In select cases, chemotherapy and radiation therapy may offer a survival benefit, underlining the importance of individualized treatment strategies based on the specific characteristics of the tumor and the patient

Primary delayed gastric emptying after pylorus-resecting pancreatoduodenectomy: A matched-pair comparison of Roux-en-Y vs. Billroth-II reconstruction

BackgroundAfter pylorus-resecting pancreatoduodenectomy (PrPD), delayed gastric emptying (DGE) might partially be attributed to biliary reflux. We investigated whether the incidence of primary DGE is reduced after Roux-en-Y instead of Billroth-II reconstruction. MethodsPatients undergoing PrPD from 2016 to 2019 at a high-volume center were identified. Excluding causes of secondary DGE, we matched patients with Roux-en-Y and Billroth-II reconstruction in a 1:2 ratio and compared primary DGE. ResultsIn 24 vs. 48 (Roux-en-Y vs. Billroth-II) patients, DGE (grade B/C) incidence (20.8 % vs. 18.8 %; p = 1.000), nasogastric tube requirement (median 2 vs. 2 days; p = 0.844) and time to solid food intake (7 vs. 7 days; P = 0.933) were comparable. Univariable logistic regression showed no association between DGE and Roux-en-Y reconstruction (OR 1.47; p = 0.524), in contrast to age (1.08; P = 0.030) and pancreatic biochemical leak (4.98; p = 0.007). ConclusionsPrimary DGE did not differ between Roux-en-Y and Billroth-II reconstruction after PrPD. Instead, age and postoperative pancreatic biochemical leak were associated with higher DGE risk.

The Impact of Travel Distance on Patient-Reported Outcomes Following Primary Total Hip Arthroplasty

BackgroundTotal hip arthroplasties (THAs) are increasingly being performed at high-volume centers, causing some patients to travel further distances to receive care. Concerns remain that increased travel distance limits follow-up, which may impact outcomes and early return to the hospital. The purpose of this study is to evaluate the impact of travel distance on 90-day patient-reported outcomes (PROs) and 90-day complication rates. MethodsPatients undergoing inpatient primary THA at a single center by one of three surgeons between 2017 and 2021 were retrospectively reviewed. Patients whose local and distant medical records were available were included. Patients who lived ≥ 40 miles from the location or follow-up were labeled as “travelers,” and those < 40 miles were “locals.” Primary outcomes included PROs as measured by Veterans Rand 12 Item Health Survey, Harris Hip Score, and Hip Dysfunction and Osteoarthritis Outcome Score for Joint Replacement. Secondary outcomes included rates of 90-day medical complications, emergency department visits, unplanned readmissions, and reoperations. ResultsA total of 413 patients were analyzed at a mean of 897.1 days (range, 92 to 2,196) including 96 travelers. Travelers averaged 96.1 miles for follow-up (range, 40.1 to 678 miles), and locals averaged 14.1 miles for follow-up (range, 0.3 to 39.8 miles). There were no differences in the percentage of patients achieving minimal clinically important difference in PROs. There was no difference in the rate of 90-day medical complications, 90-day readmissions, and reoperations. Local patients were significantly more likely to have unplanned postoperative emergency department visits (travelers = 0%, locals = 7.4%, P = 0.003). ConclusionsTravelers did not demonstrate any significant differences with respect to rates of achieving minimal clinically important difference in PROs or 90-day complication rates. These data suggest that increased travel distance to treatment centers does not impact outcomes following primary THA.

CARINAL RECONSTRUCTION FOR LUNG CANCER AND AIRWAY TUMORS: LONG-TERM RESULTS

Resection and reconstruction of the carina infiltrated by NSCLC or airway tumor is a technically demanding operation allowing oncologic radical treatment. Hereby we report the results of a 20-year experience from a high-volume center. Forty-one patients underwent carinal resection for NSCLC (n=32) or primary airway tumor (n=9). Right tracheal-sleeve pneumonectomy was performed in 19 patients, left tracheal-sleeve pneumonectomy in 6, isolated carinal resection in 4 and right tracheal-sleeve upper lobectomy in 12. In 8 patients Superior Vena Cava replacement was associated. Extra-Corporeal-Membrane-Oxygenation was used in 4 patients undergoing isolated carinal reconstruction. Nine patients received neoadjuvant chemotherapy. Complete resection (R0) was achieved in 97.5% of patients. Postoperative 30-day mortality was 7.3%(n=3). The major complication rate was 24.3%(n= 10). Airway complications were 7 (2 anastomotic fistula, 5 anastomotic stenosis requiring dilatation and stenting); other major complications included 1 esophageal-pleural fistula, 1 pneumonia and 1 pulmonary edema. Among the 32 NSCLC patients, 26 were pathologic stage III and 6 pathologic stage II. The recurrence rate was 34.2%(n=13); it was 41.3%(n=12) in NSCLC and 11.1% (n=1) in airway tumors. Three and 5-year Overall Survival (Kaplan-Meier) was 56.1% (NSCLC:50.8%;Airway:76.2%) and 50.5% (NSCLC:44.5%;Airway:76.2%), respectively. Disease-Free Survival was 61.7% (NSCLC:55.2%;Airway:85.7%) at 3 years and 55.5% (NSCLC:48.3%;Airway:85.7%) at 5 years. Carinal reconstruction for lung and airway tumors resection is a complex, oncologically reliable procedure allowing good long-term results in adequately selected patients. Wherever possible, these operations should include parenchymal sparing techniques allowing to spare healthy lung tissue without compromising the radicality of resection.

337 - Management of rectal prolapse in octogenarians: lesson learned in 13 years’ experience from a high-volume center

337 - Management of rectal prolapse in octogenarians: lesson learned in 13 years’ experience from a high-volume center

Modified reconstruction approach after pancreaticoduodenectomy optimizes postoperative outcomes: Results from a multivariate cohort analysis.

Despite technical advances in recent decades and a decrease in hospital mortality (<5%), pancreaticoduodenectomy (PD) is still associated with major postoperative complications, even in high-volume centers. The present study aimed to assess the effect of a modified reconstruction technique on postoperative morbidity and mortality. A cohort study of all patients (n=218) undergoing PD between January 2010 and December 2019 was performed at Attikon University Hospital (Athens, Greece). Several variables were studied, including demographic data, past medical history, perioperative parameters, tumor markers and pathology, duration of hospitalization, postoperative complications, 30-day-survival, postoperative mortality and overall survival using multivariate logistic regression and survival analysis techniques. In this cohort, 123 patients [modified PD (mPD) group] underwent a modified reconstruction after a pylorus-preserving pancreaticoduodenectomy, which consisted of gastrojejunostomy and pancreaticojejunostomy on the same loop and an isolated hepaticojejunostomy on another loop. In the standard PD (StPD) group, 95 patients underwent standard reconstruction. The median age was 67 years, ranging from 25 to 89 years. Compared with in the StPD group, the mPD group had significantly lower rates of grade B and C pancreatic fistula (4.9% vs. 28.4%), delayed gastric emptying (7.3% vs. 42.1%), postoperative hemorrhage (3.3% vs. 20%), intensive care unit admission (8.1% vs. 18.9%), overall morbidity (Clavien-Dindo grade III-V: 14.7% vs. 42.0%), perioperative mortality (4.1% vs. 14.7%), and shorter hospitalization stay (11 days vs. 20 days). However, no difference was noted regarding median survival (35 months vs. 30 months). In this single-center series, a modified reconstruction after PD appears to be associated with improved postoperative outcomes. However, further evaluation in larger multi-center trials is required.

Characteristics of long-term survivors with malignant pleural mesothelioma

Pleural mesothelioma (PM) is a cancer with usually a dismal prognosis. However, long-term survivors do exist. Herein, we analyzed long-term survivors (>5 years after surgery) from high-volume centres around the world. This is a multicenter retrospective descriptive analysis of long-term survivors (overall survival ≥ 5 years from surgery) treated within a multimodality therapy approach including macroscopic complete resection. Overall survival was calculated with Kaplan Meier analysis and cases were matched by center and surgery year and compared with a control group of short-term survivors (<2 years) in a conditional logistic regression analysis. There were 276 long-term survivors, most were male (n=166, 63%) with a median age of 59 (range 21-83) years at time of diagnosis. The histology for 246 was epithelioid and non-epithelioid for 30 patients. The disease was on the right side in 58% of the patients. As of this analysis, 148 patients were dead, 104 were alive and 10 were lost to follow-up. Pathological tumor stages were: pT1 (n=50), pT2 (n=63), pT3 (n=90) or pT4 (n=16), pN0 (n=150), pN1 (n=20) and pN2 (n=39). The matched control dataset included 333 patients, 95 cases and 238 controls. Comparing short- with long-term survivors, there was moderate evidence that a low white blood cell (WBC) count before surgery was more often observed in long-term survivors. The data show that long-term survival in PM is possible in a subgroup of surgically treated patients; histological subtype and WBC count seem to be prognosticators for longer survival.

Prediction of Late Proximal Endoleak Risk after EVAR by Preoperative Estimation of Endograft/Aortic Neck Apposition Surface

The aim of this study was to evaluate a new measurement tool for the pre-operative computed tomography (CT) scan to estimate the endograft apposition surface on the proximal aortic neck of the aneurysm that would predict the risk of late type IA endoleak (EL1A). From databases of four high-volume centres, between 2004 and 2020 all patients who underwent EVAR with the possibility of analysing pre- and post-EVAR scans and who presented late (>2 years) EL1A in follow-up were included retrospectively (EL1A group). A control group of randomly selected EL1A-free patients were included (control group) and follow-up beyond four years. The measurement tool (Endosize®, Therenva) was used to model a virtual cylinder constrained by the centreline whose diameter was determined from the diameter of the implanted endograft. The apposition surface was calculated by determining the areas of the virtual cylinder mesh outside the mesh of the neighbouring portion of the segmented aorta by an intersection calculation of surface normals. This apposition surface and the usual anatomical data of the proximal neck were compared between the groups with univariate and multivariate analyses. Intra- and inter-observer variability in the measurement of apposition surface was analyzed using the intraclass correlation coefficient (ICC) and the method of Bland and Altman. Sixty-six comparable patients were included, 33 in the EL1A group and 33 in the control group. The mean time to EL1A onset was 50.2 ± 24.6 months in the EL1A group and the mean follow-up time was 79.8 ± 26.8 months in the control group. In univariate analysis, only the endograft apposition surface ratio on the proximal neck was significantly lower in the EL1A group compared with the control group (50.3% vs. 75.5%; p <0.0001). There was no significant difference in classic anatomical neck characteristics. There was no difference in proximal endograft oversizing or in the length from the lowest renal artery to the beginning of the covered portion of the endograft. In multivariate analysis, only the apposition surface ratio was independently correlated with the presence of EL1A (p <0.0001). The estimation of the intra- and inter-observer variability, indicates excellent reliability (ICC = 0.992; ICC = 0.956). The method estimating the pre-operative endograft apposition surface on the proximal aortic neck appears to be a reliable measuring in predicting the risk of occurrence of late EL1A after EVAR.